(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌
| 中文名称 | (8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 |
|---|---|
| 中文同义词 | (8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌;化合物 T15054 |
| 英文名称 | Daun02 |
| 英文同义词 | Daun02;(8S,10S)-8-Acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-(beta-D-galactopyranosyloxy)-3-nitrophenyl]methoxy]carbonyl]amino]-alpha-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione;DAUN 02; DAUN-02;5,12-Naphthacenedione, 8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-(β-D-galactopyranosyloxy)-3-nitrophenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- |
| CAS号 | 290304-24-4 |
| 分子式 | C41H44N2O20 |
| 分子量 | 884.79 |
| EINECS号 | |
| 相关类别 | 细胞周期 |
| Mol文件 | 290304-24-4.mol |
| 结构式 | ![(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 结构式](CAS/20180808/GIF/290304-24-4.gif) |
(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 性质
| 沸点 | 1128.4±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.67±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 不溶于水；不溶于乙醇；超声波检测下 DMSO 中≥17.92 mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 7.39±0.60(Predicted) |
(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 用途与合成方法
|
Topoisomerase
|
Daunorubicins/Doxorubicins
|
Daun02 is a prodrug, which is converted by β-galactosidase to Daunorubicin, which has been shown to reduce calcium ion (Ca 2+ )-dependent action potentials in neuroblastoma cells. Daunorubicin is a topoisomerase inhibitor. Daun02 is a good substrate for β-galactosidase (β-gal). The concentration of Daun02 producing 50% (EC 50 ) decrease in cell viability is 0.5 μM, 1.5 μM, and 3.5 μM for T47-D, Panc02, and MCF-7, respectively.
Daun02 is a good substrate for β-gal with K m and V max values of 0.37 mM and 8.6 μmol/min/mg protein. At a concentration of 10 -5 M, Daun02 is 79% bound to plasma protein compares to 94% for Daunomycin.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-13061 | (8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 Daun02 | 290304-24-4 | 2mg | 1800元 |
| 2024/01/25 | HY-13061 | (8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 Daun02 | 290304-24-4 | 5mg | 2800元 |